Genentech pays Alector $100M for preclinical Parkinson’s prospect

Biotech Genentech pays Alector $100M for preclinical Parkinson’s prospect By Nick Paul Taylor Oct 5, 2026 10:09am Alector Genentech Roche Licensing deals Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver of neurodegeneration in Parkinson’s disease. The deal covers AL050, an investigational enzyme replacement therapy enabled by Alector’s blood-brain barrier delivery platform. Parkinson’s patients with GBA mutations have low levels of glucocerebrosidase (GCase) function.

Researchers have linked GCase deficiency to accumulation of alpha-synuclein, a protein that forms toxic clumps in Parkinson’s patients. AL050 pairs an engineered version of GCase, which Alector optimized to increase enzymatic activity and half-life, with technology for shuttling therapies into the brain. The design reflects Alector’s belief that enzyme activity and durability, plus brain penetration, are the key barriers to treating GCase deficiency.

Roche’s Genentech is betting that Alector has overcome the barriers. In addition to the upfront payment, Genentech is committing up to $1.17 billion in milestones alongside tiered royalties on net sales. The royalty rate ranges from single-digit to double-digit percentages.

Genentech will be responsible for development, regulatory affairs, manufacturing and commercialization across all indications. Alector retains ownership of its platform for delivering AL050 to the brain. Finding ways to take molecules into the brain is central to Roche’s work in neurodegenerative disease, where it is focused on testing drugs that harness transferrin receptors to cross the barrier.

In July, Roche’s head of neuroscience early development Luka Kulic, M.D., Ph.D., told Fierce that the company is “open to exploring different ways to overcome the blood-brain barrier.” Alector disclosed the Genentech deal alongside an agreement with Spur Therapeutics. The biotech took up its option on a Spur deal involving engineered GCase patents. Having paid $500,000 for the option, Alector will pay $15 million to pull the trigger in the deal.

Spur will receive “a percentage in the teens of any milestone” that Alector receives from sublicensing the patents, including from the Genentech deal. Striking the Genentech pact secures the future of AL050. As of February, Alector was aiming to file to test AL050 in humans in 2027.

However, the biotech dropped that target in May, telling investors that it was evaluating its timeline to the clinic. The deal also extends Alector’s cash runway. The South San Francisco-based biotech, which ended September with $138.7 million in the bank, previously guided that its cash runway would extend “at least through 2027.” The company now calculates it has the cash to fund operations into 2029, providing resources to develop candidates against amyloid-beta, tau and alpha-synuclein.

The secret to a successful Big Pharma dealmaking strategy is one of the hot topics being discussed at Fierce Biotech's high-impact event in London next month. Find out more information and register by clicking on the banner below: Where Big Pharma Is Placing Its Bets Alector Genentech Roche Licensing deals Parkinson's disease enzyme disorders Blood-brain barrier Biotech Deals